Illinois General Assembly - Full Text of HB0342
Illinois General Assembly

Previous General Assemblies

Full Text of HB0342  101st General Assembly

HB0342ham001 101ST GENERAL ASSEMBLY

Rep. Darren Bailey

Filed: 2/26/2019

 

 


 

 


 
10100HB0342ham001LRB101 04865 RPS 56199 a

1
AMENDMENT TO HOUSE BILL 342

2    AMENDMENT NO. ______. Amend House Bill 342 by replacing
3everything after the enacting clause with the following:
 
4    "Section 5. The Department of Public Health Powers and
5Duties Law of the Civil Administrative Code of Illinois is
6amended by adding Section 2310-578 as follows:
 
7    (20 ILCS 2310/2310-578 new)
8    Sec. 2310-578. Immunizing agents derived from aborted
9fetal tissue.
10    (a) As used in this Section:
11        (1) "Health care provider" means any physician,
12    advanced practice registered nurse, physician assistant,
13    hospital facility, or other person that is licensed or
14    otherwise authorized to deliver health care services.
15        (2) "Immunizing agent derived from aborted fetal
16    tissue" means an immunizing agent that is manufactured

 

 

10100HB0342ham001- 2 -LRB101 04865 RPS 56199 a

1    using a human fetal or embryonic cell line, protein,
2    deoxyribonucleic acid, recombinant deoxyribonucleic acid,
3    monoclonal antibody, or any other component derived from an
4    elective abortion or using a cell line derived from the
5    tissue of a fetus that was electively aborted.
6    (b) The Department shall create and maintain a list of each
7immunizing agent derived from aborted fetal tissue. If an
8immunizing agent that is not an immunizing agent derived from
9aborted fetal tissue is available as an alternative to an
10immunizing agent derived from aborted fetal tissue, the
11Department shall include the alternative on the list. The
12Department shall update the list annually and make the list
13available to the public on the Department's website.
14    (c) The Department shall ensure that, beginning January 1,
152020, before administering an immunizing agent derived from
16aborted fetal tissue to an individual, a health care provider
17shall notify the individual or, if the individual is a child,
18the parent or guardian of the child that the immunizing agent
19was derived from aborted fetal tissue. If an immunizing agent
20that is not an immunizing agent derived from aborted fetal
21tissue is available as an alternative to an immunizing agent
22derived from aborted fetal tissue, the health care provider
23shall offer the alternative to the individual or, if the
24individual is a child, to the parent or guardian of the child.
25A health care provider shall also notify the individual or, if
26the individual is a child, the parent or guardian of the child

 

 

10100HB0342ham001- 3 -LRB101 04865 RPS 56199 a

1of the option to decline the receipt of the immunizing agent.
 
2    Section 99. Effective date. This Act takes effect upon
3becoming law.".